MCID: INS001
MIFTS: 66

Insulinoma

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Insulinoma

MalaCards integrated aliases for Insulinoma:

Name: Insulinoma 37 12 72 49 55 28 51 41 14 69
Islet Cell Adenoma 12 69
Experimental Organism Islet Cell Adenoma Neoplasm 69
Insulin-Producing Tumor of Islet Cells 12
Adenoma Islet Cell 51
Islet Cell Tumor 69

Characteristics:

Orphanet epidemiological data:

55
insulinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Ireland),1-9/1000000 (Worldwide),1-9/1000000 (Japan); Age of onset: All ages;

Classifications:



Summaries for Insulinoma

NIH Rare Diseases : 49 Insulinoma is a type of pancreatic neuroendocrine tumor (pancreatic NET), which refers to a group of rare tumors that form in the hormone-making cells of the pancreas. Insulinomas, specifically, produce too much insulin, a hormone that reduces the level of sugar in the blood by helping it move into cells. As a result, people with insulinomas generally have very low blood sugar levels which can be associated with anxiety, confusion, hunger, a fast heart rate, and sweating. In severe cases, it can lead to seizures, coma or even death. Ninty percent of insulinomas are benign (noncancerous). In most cases, the underlying cause of insulinoma is unknown. However, people with specific genetic syndromes such as multiple endocrine neoplasia type I, Von Hippel-Lindau syndrome, Neurofibromatosis type 1, and tuberous sclerosis are at risk of insulinomas and other endocrine tumors. Treatment generally includes surgery to remove the tumor. Last updated: 4/26/2016

MalaCards based summary : Insulinoma, also known as islet cell adenoma, is related to glucagonoma and pancreatic islet cell tumors, and has symptoms including hearing abnormality, abnormality of vision and anxiety. An important gene associated with Insulinoma is INSM1 (INSM Transcriptional Repressor 1), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Glucose / Energy Metabolism. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, the pancreas and pancreas, and related phenotypes are endocrine/exocrine gland and digestive/alimentary

Disease Ontology : 12 An adenoma that is located in the pancreas and is characterized by overproduction of insulin.

Wikipedia : 72 An insulinoma is a tumor of the pancreas that is derived from beta cells and secretes insulin. It is a... more...

Related Diseases for Insulinoma

Diseases related to Insulinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 169)
# Related Disease Score Top Affiliating Genes
1 glucagonoma 30.1 CHGA SCT SST
2 pancreatic islet cell tumors 30.1 INS MEN1 SST
3 hyperproinsulinemia 30.0 INS SCT
4 hypoglycemia 29.9 ABCC8 GCG GCK INS
5 duodenal ulcer 29.9 INS SCT SST
6 neuroendocrine tumor 29.8 CHGA INSM1 MEN1 SST
7 multiple endocrine neoplasia, type i 29.7 CHGA INS MEN1 SCT SST
8 hyperinsulinism 29.7 ABCC8 GCK INS SST
9 islet cell tumor 29.6 CHGA INS MEN1 SST
10 hyperinsulinemic hypoglycemia 29.5 ABCC8 GCK INS MEN1 SST
11 gastrinoma 29.4 CHGA INS MEN1 SCT SST
12 hyperinsulinemic hypoglycemia, familial, 2 29.3 ABCC8 CHGA INS SCT SST
13 zollinger-ellison syndrome 29.2 CHGA MEN1 SCT SST
14 glucose intolerance 29.0 GCG GCK INS
15 dumping syndrome 28.8 GCG INS SCT SST
16 body mass index quantitative trait locus 11 28.6 GCG GCK GLP1R IAPP INS SLC2A2
17 diabetes mellitus 27.0 ABCC8 GCG GCK IAPP INS MEN1
18 hyperglycemia 26.5 ABCC8 GCG GCK GLP1R IAPP INS
19 insulinoma tumor suppressor gene locus 12.1
20 metastatic insulinoma 12.0
21 adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia 11.9
22 pancreatitis 10.6
23 microinvasive cervical squamous cell carcinoma 10.5 INSM1 PTPRN
24 fallopian tube endometrioid adenocarcinoma 10.5 INSM1 PTPRN
25 maturity-onset diabetes of the young, type 2 10.5 GCK INS
26 duodenal somatostatinoma 10.4 INS SST
27 fallopian tube adenocarcinoma 10.4 INSM1 PTPRN
28 postgastrectomy syndrome 10.4 INS SST
29 postural hypotension 10.4 INS SST
30 pancreatic somatostatinoma 10.4 MEN1 SST
31 hormone producing pituitary cancer 10.4 MEN1 SST
32 type 1 diabetes mellitus 13 10.3 INS PTPRN
33 type 1 diabetes mellitus 7 10.3 INS NEUROD1 PTPRN
34 pituitary gland disease 10.3 INS MEN1 SST
35 duodenal gastrinoma 10.3 MEN1 SCT
36 hyperpituitarism 10.3 INS SST
37 multiple endocrine neoplasia 10.3
38 acromegaly 10.3 INS MEN1 SST
39 hyperinsulinemic hypoglycemia, familial, 3 10.2 ABCC8 GCK
40 munchausen by proxy 10.2 ABCC8 GCK
41 gestational diabetes 10.2 GCK INS PTPRN
42 hepatitis 10.2
43 pancreatic agenesis 1 10.2 PDX1 SCT
44 gastrointestinal neuroendocrine benign tumor 10.2 CHGA SST
45 gastric neuroendocrine neoplasm 10.2 CHGA SST
46 adenoma of the pancreas 10.2 CHGA SST
47 angiodysplasia 10.1 SCT SST
48 diarrhea 4, malabsorptive, congenital 10.1 CHGA NEUROD1
49 factitious disorder 10.1 ABCC8 GCK INS
50 type 1 diabetes mellitus 15 10.1 GCG INS

Graphical network of the top 20 diseases related to Insulinoma:



Diseases related to Insulinoma

Symptoms & Phenotypes for Insulinoma

Human phenotypes related to Insulinoma:

55 31 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hearing abnormality 55 31 occasional (7.5%) Occasional (29-5%) HP:0000364
2 abnormality of vision 55 31 occasional (7.5%) Occasional (29-5%) HP:0000504
3 anxiety 55 31 occasional (7.5%) Occasional (29-5%) HP:0000739
4 hyperinsulinemic hypoglycemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0000825
5 hyperhidrosis 55 31 hallmark (90%) Very frequent (99-80%) HP:0000975
6 seizures 55 31 hallmark (90%) Very frequent (99-80%) HP:0001250
7 lethargy 55 31 occasional (7.5%) Occasional (29-5%) HP:0001254
8 coma 55 31 occasional (7.5%) Occasional (29-5%) HP:0001259
9 tremor 55 31 hallmark (90%) Very frequent (99-80%) HP:0001337
10 nonketotic hypoglycemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001958
11 palpitations 55 31 hallmark (90%) Very frequent (99-80%) HP:0001962
12 recurrent hypoglycemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001988
13 zollinger-ellison syndrome 55 31 frequent (33%) Frequent (79-30%) HP:0002044
14 abnormal rapid eye movement sleep 55 31 occasional (7.5%) Occasional (29-5%) HP:0002494
15 polyphagia 55 31 frequent (33%) Frequent (79-30%) HP:0002591
16 generalized muscle weakness 55 31 frequent (33%) Frequent (79-30%) HP:0003324
17 paresthesia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003401
18 increased body weight 55 31 frequent (33%) Frequent (79-30%) HP:0004324
19 abnormality of the pancreatic islet cells 55 31 hallmark (90%) Very frequent (99-80%) HP:0006476
20 pituitary prolactin cell adenoma 55 31 frequent (33%) Frequent (79-30%) HP:0006767
21 fluctuations in consciousness 55 31 frequent (33%) Frequent (79-30%) HP:0007159
22 primary hyperparathyroidism 55 31 frequent (33%) Frequent (79-30%) HP:0008200
23 fasting hyperinsulinemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0008283
24 transient global amnesia 55 31 hallmark (90%) Very frequent (99-80%) HP:0010534
25 abnormality of pain sensation 55 31 occasional (7.5%) Occasional (29-5%) HP:0010832
26 reactive hypoglycemia 55 31 frequent (33%) Frequent (79-30%) HP:0012051
27 fatigue 55 31 occasional (7.5%) Occasional (29-5%) HP:0012378
28 neoplasm of the adrenal gland 55 31 occasional (7.5%) Occasional (29-5%) HP:0100631
29 neuroendocrine neoplasm 55 31 occasional (7.5%) Occasional (29-5%) HP:0100634
30 insomnia 55 31 occasional (7.5%) Occasional (29-5%) HP:0100785
31 behavioral abnormality 55 Frequent (79-30%)
32 hyperinsulinemia 55 Very frequent (99-80%)
33 reduced consciousness/confusion 55 Frequent (79-30%)
34 abnormality of higher mental function 55 Occasional (29-5%)

MGI Mouse Phenotypes related to Insulinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.93 ABCC8 CHGA GCK GLP1R INS INSM1
2 digestive/alimentary MP:0005381 9.8 INS INSM1 MEN1 NEUROD1 PDX1 SST
3 growth/size/body region MP:0005378 9.73 CHGA GCK GLP1R IAPP INS INSM1
4 homeostasis/metabolism MP:0005376 9.5 INSM1 KCNA5 MEN1 NEUROD1 PDX1 PTPRN

Drugs & Therapeutics for Insulinoma

Drugs for Insulinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
4
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
5
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
6
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
7
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6 32051 23994
8 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
9 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
12 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Hypoglycemic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
21 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
22 insulin Phase 4,Phase 2
23 Insulin, Globin Zinc Phase 4,Phase 2
24 Fluorodeoxyglucose F18 Phase 4,Phase 2
25
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
26
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
27
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
28
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30 lanreotide Approved Phase 3,Phase 2 108736-35-2
31
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
34 Antimetabolites Phase 2, Phase 3,Phase 1
35 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
36 Anesthetics Phase 3
37 Calcimimetic Agents Phase 3
38 Calcium, Dietary Phase 3,Phase 2,Phase 1
39 Cinacalcet Hydrochloride Phase 3
40 Adjuvants, Anesthesia Phase 3
41 Analgesics Phase 3
42 Analgesics, Opioid Phase 3
43 Anesthetics, General Phase 3
44 Anesthetics, Intravenous Phase 3
45 Central Nervous System Depressants Phase 3,Phase 2,Not Applicable
46 Narcotics Phase 3
47 Peripheral Nervous System Agents Phase 3,Phase 2
48 Angiopeptin Phase 3,Phase 2
49 Pharmaceutical Solutions Phase 3,Phase 2
50 Dihydroxyphenylalanine Phase 3

Interventional clinical trials:

(show top 50) (show all 161)

# Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
3 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
4 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
5 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
6 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
7 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
8 Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor Unknown status NCT02330497 Phase 3
9 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
10 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
12 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
13 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
14 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
15 Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Sulfatinib
16 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
17 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
18 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
19 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
20 Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
21 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
22 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
23 Effect of Gelofusine on GLP1-receptor Imaging Completed NCT02541734 Phase 1, Phase 2 Gelofusine;Placebo
24 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
25 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
26 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
27 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
28 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
29 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
30 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
31 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
32 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
33 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
34 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
35 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
36 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
37 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01121562 Phase 2 Sunitinib
38 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
39 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
40 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
41 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Completed NCT01673906 Phase 2 Diagnostic work up
42 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
43 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
44 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 68Ga-OPS202
45 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
46 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
47 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
48 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib
49 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
50 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan

Search NIH Clinical Center for Insulinoma

Cochrane evidence based reviews: insulinoma

Genetic Tests for Insulinoma

Genetic tests related to Insulinoma:

# Genetic test Affiliating Genes
1 Insulinoma 28

Anatomical Context for Insulinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Insulinoma:

18
The Pancreas

MalaCards organs/tissues related to Insulinoma:

38
Pancreas, Liver, Heart, Testes, Pancreatic Islet, Pituitary, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Insulinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease

Publications for Insulinoma

Articles related to Insulinoma:

(show top 50) (show all 941)
# Title Authors Year
1
Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens. ( 29360191 )
2018
2
Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. ( 29175872 )
2018
3
<i>Nfe2l1-</i> silenced insulinoma cells acquire aggressiveness and chemoresistance. ( 29203613 )
2018
4
Insulinoma-associated 1: A novel nuclear marker in Merkel cell carcinoma (cutaneous neuroendocrine carcinoma). ( 29148079 )
2018
5
Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. ( 29314520 )
2018
6
17I^-estradiol protects INS-1 insulinoma cells from mitophagy via G protein-coupled estrogen receptors and the PI3K/Akt signaling pathway. ( 29436590 )
2018
7
An observational analysis of insulinoma from 1 single institution. ( 29319794 )
2018
8
Clinical Value of<sup>18</sup>F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. ( 29277794 )
2018
9
Insulinoma presenting with post-prandial hypoglycaemia following fundoplication. ( 29367876 )
2018
10
T372R Mutation Status in Yin Yang 1 Gene in Insulinoma Patients. ( 28472826 )
2017
11
Geniposide improves insulin production and reduces apoptosis in high glucose-induced glucotoxic insulinoma cells. ( 28363490 )
2017
12
Successful EUS-guided ethanol ablation of insulinoma, four-year follow-up. Case report and literature review. ( 28819950 )
2017
13
Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma. ( 28230660 )
2017
14
Selective Arterial Calcium Stimulation with Hepatic Venous Sampling in Patients with Recurrent Endogenous Hyperinsulinemic Hypoglycemia and Metastatic Insulinoma: Evaluation in Five Patients. ( 29157479 )
2017
15
Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor. ( 28849340 )
2017
16
Association of Insulinoma and Type 2 Diabetes Mellitus. ( 28835758 )
2017
17
Recurrence of Metastatic Pro-insulinoma Nearly 50A Years After Subtotal Pancreatectomy. ( 29110229 )
2017
18
A case of long-survival insulinoma with multiple neuroendocline tumour type 1 controlled by multimodal therapy. ( 29250314 )
2017
19
Prospective comparison of biphasic contrast-enhanced CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection. ( 28419614 )
2017
20
A severe but reversible reduction in insulin sensitivity is observed in patients with insulinoma. ( 29241949 )
2017
21
Erratum: Correction of Figure. Clinical Implications of Various Criteria for the Biochemical Diagnosis of Insulinoma. ( 28685521 )
2017
22
Seizures Due to Insulinoma- A Rare but Treatable Cause. ( 28462560 )
2017
23
Insulinoma Presenting with Neuropsychiatric Symptoms. ( 28782321 )
2017
24
Insulinoma - The incremental value of somatostatin receptor positron emission tomography. ( 28217530 )
2017
25
Synchronous solid pseudopapillary tumor and insulinoma in an adolescent MEN1 patient presenting with diagnostic dilemmas. ( 28663159 )
2017
26
Insulinoma enucleation after echoendoscopic fiducialA placement. ( 28807758 )
2017
27
Postprandial hypoglycemia as the only manifestation of insulinoma: exceptional case report. ( 28416239 )
2017
28
Giant insulinoma: an unusual cause of hypoglycaemia. ( 29167186 )
2017
29
(68)Ga-DOTATATE PET/CT Can Be an Alternative Imaging Method in Insulinoma Patients. ( 28798227 )
2017
30
Endoscopic ultrasound-guided ethanol ablation therapy for pancreatic insulinoma: an unusual strategy. ( 28458908 )
2017
31
Endoscopic Ultrasound-Guided Ethanol Ablation for Control of Local-Regional Metastatic Insulinoma. ( 28187109 )
2017
32
Characteristics of glucose metabolism indexes and continuous glucose monitoring system (CGMS) in patients with insulinoma. ( 28293303 )
2017
33
Hypoglycemia and decreased insulin requirement caused by malignant insulinoma in a type 1 diabetic patient: when the hoof beats are from a zebra, not a horse. ( 28588806 )
2017
34
Stimulation of B-Raf increases c-Jun and c-Fos expression and upregulates AP-1-regulated gene transcription in insulinoma cells. ( 29225069 )
2017
35
Insulinoma Detection With MDCT: Is There a Role for Whole-Pancreas Perfusion? ( 27929662 )
2017
36
Non-surgical ablative therapies for inoperable benign insulinoma. ( 28755102 )
2017
37
Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression. ( 28071719 )
2017
38
Insulinoma and Chronic Kidney Disease: An Uncommon Conundrum Not to Be Overlooked. ( 29200897 )
2017
39
Small pancreatic insulinoma: Successful endoscopic ultrasound-guided radiofrequency ablation in a single session using a 22-G fine needle. ( 28295664 )
2017
40
Case of insulinoma manifesting as hyperinsulinemia after discontinuing quetiapine in an elderly patient with delirium. ( 28508501 )
2017
41
A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases. ( 27908529 )
2017
42
Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization be Evaluated at 60 or 120 Seconds? ( 28943589 )
2017
43
Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality? ( 29264566 )
2017
44
Development of (111)In-labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma. ( 28089587 )
2017
45
Pyruvate kinase M1 interacts with A-Raf and inhibits endoplasmic reticulum stress-induced apoptosis by activating MEK1/ERK pathway in mouse insulinoma cells. ( 28743549 )
2017
46
Laparoscopic surgery for solitary insulinoma in the absence of IOUS. ( 28782747 )
2017
47
Baicalein protects rat insulinoma INS-1 cells from palmitate-induced lipotoxicity by inducing HO-1. ( 28445528 )
2017
48
Glucagon-like peptide-1 receptor agonist exendin-4 protects against interleukin-1I^-mediated inhibition of glucose-stimulated insulin secretion by mouse insulinoma I^ cells. ( 28947919 )
2017
49
Insulinoma-associated protein 1 (INSM1) differentiates carcinoid tumourlets of the lung from pulmonary meningothelial-like nodules. ( 29274092 )
2017
50
Ultrasonographic features of insulinoma in six ferrets. ( 28699200 )
2017

Variations for Insulinoma

Expression for Insulinoma

Search GEO for disease gene expression data for Insulinoma.

Pathways for Insulinoma

Pathways related to Insulinoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.54 ABCC8 GCG GCK GLP1R INS PDX1
2 12.28 GCG INS NEUROD1 PDX1 WFS1
3
Show member pathways
12.18 GCG GLP1R IAPP SCT
4
Show member pathways
12.13 ABCC8 GCG GLP1R INS SLC2A2
5 11.92 GCG GLP1R IAPP SCT
6 11.86 INS NEUROD1 PDX1 SLC2A2
7
Show member pathways
11.75 GCK INS NEUROD1 PDX1 SLC2A2
8 11.68 GCG GCK SLC2A2
9
Show member pathways
11.42 ABCC8 GCK INS NEUROD1 PDX1 SLC2A2
10 11.2 ABCC8 GCK INS PDX1 SLC2A2
11
Show member pathways
11.17 GCK IAPP INS INSM1 NEUROD1 PDX1
12 10.71 INS SLC2A2

GO Terms for Insulinoma

Cellular components related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.92 GCG INS MEN1 WFS1

Biological processes related to Insulinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.88 GCG IAPP INS SCT SST
2 cellular protein metabolic process GO:0044267 9.8 IAPP INS MEN1 WFS1
3 glucose metabolic process GO:0006006 9.63 GCK INS PDX1
4 positive regulation of cell differentiation GO:0045597 9.61 INS INSM1 NEUROD1
5 nitric oxide mediated signal transduction GO:0007263 9.58 NEUROD1 PDX1
6 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.58 PDX1 WFS1
7 cellular glucose homeostasis GO:0001678 9.57 ABCC8 GCK
8 positive regulation of glycogen biosynthetic process GO:0045725 9.56 GCK INS
9 negative regulation of gluconeogenesis GO:0045721 9.55 GCK INS
10 glucose homeostasis GO:0042593 9.55 GCK INS NEUROD1 PDX1 WFS1
11 positive regulation of cAMP metabolic process GO:0030816 9.54 CHGA IAPP
12 insulin secretion GO:0030073 9.54 NEUROD1 PDX1 PTPRN
13 regulation of potassium ion transport GO:0043266 9.52 GCK KCNA5
14 negative regulation of blood vessel diameter GO:0097756 9.51 CHGA INS
15 endocrine pancreas development GO:0031018 9.5 INSM1 NEUROD1 PDX1
16 type B pancreatic cell differentiation GO:0003309 9.43 INSM1 MEN1 PDX1
17 detection of glucose GO:0051594 9.4 GCK PDX1
18 regulation of insulin secretion GO:0050796 9.17 ABCC8 GCG GCK GLP1R KCNA5 NEUROD1
19 negative regulation of type B pancreatic cell apoptotic process GO:2000675 9.13 NEUROD1 PDX1 WFS1

Molecular functions related to Insulinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 GCG IAPP INS SCT SST

Sources for Insulinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....